OXFORD, England, Aug. 26, 2015 /PRNewswire/ -- After litigating and negotiating patent infringement claims brought by P2i Ltd against Europlasma NV relating to P2i United States patent RE43,651 (the '651 patent), the parties have resolved their dispute in the United States without any admission or concession of wrongdoing or liability on the part of either party. As a result of the parties' settlement, the US District Court for the Central District of California dismissed the case without prejudice.
Under the terms of the confidential settlement Europlasma NV has (amongst other things) agreed:
Carl Francis, P2i's CEO, commented on the settlement, "This action demonstrates P2i's resolve to protect its valuable patent portfolio from potential infringers and we are satisfied with the outcome. We take the protection of our intellectual property rights very seriously and will continue to enforce our rights worldwide."
The parties remain in dispute in other jurisdictions worldwide.
Established as the only credible provider of water repellent nano-coating technology in mass production, P2i boast monthly processing volumes that have more than tripled over the last year. The technology has now been applied to over 100 million electronic devices worldwide, as smartphone manufacturers seek to improve reliability and respond to consumer demand to provide essential protection against water damage.
About P2i
P2i is the global leader in liquid repellent nano-coatings, helping companies around the world give their products improved protection against damaging elements such as water, oil, sweat and mud. Using a patented pulsed plasma process, P2i's technology coats products with an invisible protective coating 1/1000th the thickness of a human hair. Products P2i has coated include a wide range of high-value products from mobile phones to technical clothing, footwear, hearing aids, medical devices, filtration materials and the nose cones of Formula 1 cars.
Headquartered near Oxford in England, P2i's market-leading technology is protected by over 175 granted patents. The company has three laboratory facilities in the UK, USA and China to support its continuous development work.
See http://www.p2i.com for more information.
